Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1222137.RAiYcqwOS64o2C-IBEV4pwDp2WsUCgag3PGQJUbn6iO7U130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1222137.RAiYcqwOS64o2C-IBEV4pwDp2WsUCgag3PGQJUbn6iO7U130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1222137.RAiYcqwOS64o2C-IBEV4pwDp2WsUCgag3PGQJUbn6iO7U130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1222137.RAiYcqwOS64o2C-IBEV4pwDp2WsUCgag3PGQJUbn6iO7U130_provenance.
- NP1222137.RAiYcqwOS64o2C-IBEV4pwDp2WsUCgag3PGQJUbn6iO7U130_assertion description "[Interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib were examined in non-Hodgkin lymphoma (NHL) models, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and double-hit lymphoma cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1222137.RAiYcqwOS64o2C-IBEV4pwDp2WsUCgag3PGQJUbn6iO7U130_provenance.
- NP1222137.RAiYcqwOS64o2C-IBEV4pwDp2WsUCgag3PGQJUbn6iO7U130_assertion evidence source_evidence_literature NP1222137.RAiYcqwOS64o2C-IBEV4pwDp2WsUCgag3PGQJUbn6iO7U130_provenance.
- NP1222137.RAiYcqwOS64o2C-IBEV4pwDp2WsUCgag3PGQJUbn6iO7U130_assertion SIO_000772 25239935 NP1222137.RAiYcqwOS64o2C-IBEV4pwDp2WsUCgag3PGQJUbn6iO7U130_provenance.
- NP1222137.RAiYcqwOS64o2C-IBEV4pwDp2WsUCgag3PGQJUbn6iO7U130_assertion wasDerivedFrom befree-2016 NP1222137.RAiYcqwOS64o2C-IBEV4pwDp2WsUCgag3PGQJUbn6iO7U130_provenance.
- NP1222137.RAiYcqwOS64o2C-IBEV4pwDp2WsUCgag3PGQJUbn6iO7U130_assertion wasGeneratedBy ECO_0000203 NP1222137.RAiYcqwOS64o2C-IBEV4pwDp2WsUCgag3PGQJUbn6iO7U130_provenance.
- befree-2016 importedOn "2016-02-19" NP1222137.RAiYcqwOS64o2C-IBEV4pwDp2WsUCgag3PGQJUbn6iO7U130_provenance.